As Chong Kun Dang, Yuhan Corp., and GC Pharma, one of the top three traditional pharmaceutical companies in sales, are set to launch a combination of high blood pressure + hyperlipidemia, the market is expected to lead the prescription trend in the future. Currently, the market is led by improved complexes developed by Boryung, Hanmi Pharmaceutical, and Daewoong Pharmaceutical, and it is expected to rise further if Chong Kun Dang and Yuhan are joined.

According to the MOHW on the 27th, as of May 1, Chong Kun Dang's Cantabell A, Yuhan Corp.'s Duowell Plus, and GC Pharma's Rozetel will be listed.

Chong Kun Dang's Cantabell A is a combination of ARB-based Candesartan Cilexetil, CCB-based Aml